• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Article

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

Pharmacyclics, which recently agreed to be acquired by AbbVie Inc for about $21 billion, said Imbruvica showed a statistically significant improvement in survival without disease progression, the study's main goal.

Imbruvica, which is co-marketed by Pharmacyclics and J&J, is already approved for four cancer indications in the United States.

Link to the Reuters report:

http://reut.rs/1Gijzad

Related Videos
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Cathy Eng, MD, FACP, FASCO
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Rohan Garje, MD
Susan Escudier, MD, FACP
Sabarish Ayyappan, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.